2011
Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status
Skates S, Mai P, Horick N, Piedmonte M, Drescher C, Isaacs C, Armstrong D, Buys S, Rodriguez G, Horowitz I, Berchuck A, Daly M, Domchek S, Cohn D, Van Le L, Schorge J, Newland W, Davidson S, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff N, Fabian C, Sluss P, Nayfield S, Kasten C, Finkelstein D, Greene M, Lu K. Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status. Cancer Prevention Research 2011, 4: 1401-1408. PMID: 21893500, PMCID: PMC3172691, DOI: 10.1158/1940-6207.capr-10-0402.Peer-Reviewed Original ResearchConceptsHigh-risk womenCut-pointsMenopausal statusScreening TrialOvarian Cancer Screening TrialOvarian cancer screening studiesPopulation of high-risk womenOvarian cancer screeningPremenopausal womenStandard cut-pointCancer Screening TrialCancer screening studyEffect of menopausal statusPostmenopausal subjectsClinical factorsScreening studiesOral contraceptivesCancer screeningEarly detection of ovarian cancerCA125 testDetection of ovarian cancerGynecologic Oncology GroupEligibility criteriaScreening protocolDemographic data
2006
BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50
Haile R, Thomas D, McGuire V, Felberg A, John E, Milne R, Hopper J, Jenkins M, Levine A, Daly M, Buys S, Senie R, Andrulis I, Knight J, Godwin A, Southey M, McCredie M, Giles G, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike M, Whittemore A, Investigators K. BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50. Cancer Epidemiology Biomarkers & Prevention 2006, 15: 1863-1870. PMID: 17021353, DOI: 10.1158/1055-9965.epi-06-0258.Peer-Reviewed Original ResearchMeSH KeywordsAdultAustraliaBreast NeoplasmsCanadaCarcinoma in SituCarcinoma, Ductal, BreastCase-Control StudiesContraceptives, OralFemaleGenes, BRCA1Genes, BRCA2Genetic Predisposition to DiseaseHeterozygoteHumansLogistic ModelsMiddle AgedMutationReceptors, EstrogenReceptors, ProgesteroneRisk FactorsSurveys and QuestionnairesTime FactorsUnited StatesConceptsRisk of breast cancerBRCA2 mutation carriersOral contraceptive useMutation carriersAssociated with breast cancer riskIncreased risk of breast cancerBreast cancerOral contraceptivesContraceptive useBreast cancer riskUnconditional logistic regressionDuration of oral contraceptive useBRCA1 mutation carriersDuration of useCase-control analysisEffects of oral contraceptivesCancer riskFamily historyModify practicesElevated riskLogistic regressionIncreased riskBRCA2Family relationshipsBRCA1